Compounds > sorafenib
Page last updated: 2024-09-05

sorafenib and arginyl-glycyl-aspartic acid

sorafenib has been researched along with arginyl-glycyl-aspartic acid in 3 studies

Compound Research Comparison

Studies
(sorafenib)		Trials
(sorafenib)		Recent Studies (post-2010)
(sorafenib)		Studies
(arginyl-glycyl-aspartic acid)		Trials
(arginyl-glycyl-aspartic acid)		Recent Studies (post-2010) (arginyl-glycyl-aspartic acid)
6,5207305,2514,556171,799

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Liu, YL; Wang, JL; Wang, ZH; Xi, Y; Zhang, Q1
Abiraj, K; Boerman, OC; Franssen, GM; Gerrits, D; Lok, J; Oyen, WJ; Terry, SY1
Chen, K; Li, M; Su, Y; Wang, W; Xu, L; Xu, X; Zhang, F; Zhou, J1

Other Studies

3 other study(ies) available for sorafenib and arginyl-glycyl-aspartic acid

ArticleYear
Combination of targeted PDT and anti-VEGF therapy for rat CNV by RGD-modified liposomal photocyanine and sorafenib.
    Investigative ophthalmology & visual science, 2013, Dec-05, Volume: 54, Issue:13

    Topics: Animals; Choroidal Neovascularization; Disease Models, Animal; Fluorescein Angiography; Fundus Oculi; Humans; Liposomes; Male; Niacinamide; Oligopeptides; Phenylurea Compounds; Photochemotherapy; Photosensitizing Agents; Rats; Rats, Inbred BN; Receptors, Immunologic; Sorafenib; Vascular Endothelial Growth Factor A

2013
Can 111In-RGD2 monitor response to therapy in head and neck tumor xenografts?
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2014, Volume: 55, Issue:11

    Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Cell Line, Tumor; Female; Head and Neck Neoplasms; Humans; Indium; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Niacinamide; Oligopeptides; Phenylurea Compounds; Radioisotopes; Sorafenib; Time Factors; Tissue Distribution; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed

2014
A dual-targeting reconstituted high density lipoprotein leveraging the synergy of sorafenib and antimiRNA21 for enhanced hepatocellular carcinoma therapy.
    Acta biomaterialia, 2018, 07-15, Volume: 75

    Topics: Animals; Carcinoma, Hepatocellular; Female; Hep G2 Cells; Human Umbilical Vein Endothelial Cells; Humans; Lipoproteins, HDL; Liver Neoplasms; Mice; Mice, Inbred BALB C; MicroRNAs; Oligopeptides; RNA, Neoplasm; Sorafenib

2018